

Human Coagulation factor XI (C500S) Protein, Ultra Low Endotoxin



Cat. No. FXI-HM10D-UL

Description

| | |
|-------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|
| Source | Recombinant Human Coagulation factor XI (C500S) Protein is expressed from HEK293 with His tag at the C-terminus. It contains Ile388-Val625 (C500S). |
| Accession | P03951-1 |
| Molecular Weight | The protein has a predicted MW of 28.43 kDa. Due to glycosylation, the protein migrates to 30-45 kDa based on Bis-Tris PAGE result. |
| Endotoxin | Less than 0.01 EU per µg by the LAL method. |
| Purity | > 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC |

Formulation and Storage


| | |
|-----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Formulation | Lyophilized from 0.22 µm filtered solution in 25mM HEPES, 150mM NaCl (pH 7.5). Normally 8% trehalose is added as protectant before lyophilization. |
| Reconstitution | Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions. |
| Storage | -20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles. |

Background

Coagulation factor (F)XI has been described as a component of the early phase of the contact pathway of blood coagulation, acting downstream of factor XII. In contrast to its mild hemostatic activities, FXI is known to play a significant role in thrombosis, as it is a demonstrated independent risk factor for deep vein thrombosis, ischemic stroke, and myocardial infarction. A better understanding of the varied and complex role of FXI in both thrombosis and hemostasis will help to allow better prediction of bleeding risk in FXI-deficient patients and also informing the development of targeted agents to inhibit the thrombotic activities of FXI while preserving hemostasis.

Assay Data


Bis-Tris PAGE



Human Coagulation factor XI (C500S) on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC

Assay Data




The purity of Human Coagulation factor XI (C500S) is greater than 95% as determined by SEC-HPLC.

ELISA Data

Human Coagulation factor XI (C500S), His Tag ELISA

0.05µg Human Coagulation factor XI (C500S), His Tag Per Well



Immobilized Human Coagulation factor XI (C500S), His Tag at 0.5µg/ml (100µl/well) on the plate. Dose response curve for Anti-factor XI Antibody, hFc Tag with the EC50 of 2.8ng/ml determined by ELISA.